Nurix enrolls first patient in Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed/refractory CLL/SLL

PUBT · 2d ago
Nurix enrolls first patient in Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed/refractory CLL/SLL
  • Nurix enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory CLL/SLL.
  • No new trial results were presented; the study is intended to generate future evidence to support global regulatory filings.
  • The trial will test whether BTK degradation can deliver better clinical benefit than pirtobrutinib in patients who progressed on a covalent BTK inhibitor.
  • The global study targets about 620 patients, randomizing them to bexobrutideg 600 mg once daily or pirtobrutinib.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040100PRIMZONEFULLFEED9802873) on August 04, 2026, and is solely responsible for the information contained therein.